Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department

Completed · Phase 4

Conditions studied: Hypertensive Urgency

In brief

The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.

Key facts

Study ID

NCT00765648

Run by

The Cleveland Clinic

People needed

226

Starts

2008-10-01

Expected to finish

2010-01-01

Last updated by the study team

2015-01-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Systolic blood pressure ≥180 mm Hg on 2 consecutive readings(10 minutes apart)presenting in the emergency department (ED)

You may not qualify if…

• Use of any investigational drug within 1 month prior to emergency department (ED)
• Pregnant or breast-feeding females
• Contraindications or allergy to beta-blockers and calcium channel blockers (see FDA approved labeling for nicardipine intravenous and labetalol)
• Subjects with decompensated congestive heart failure (CHF) or with a known left ventricular ejection fraction (LVEF) <35%
• History of stroke within 30 days
• Known liver failure
• Suspected myocardial infarction
• Suspected aortic dissection
• Suspected cocaine overdose
• Concurrently receiving other intravenous (I.V.) hypertensive medications

Where it is running

• Cleveland Clinic — Cleveland, Ohio, United States
• University of Texas Health Science Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.